Literature DB >> 16481664

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

James J McGough1, Sharon B Wigal, Howard Abikoff, John M Turnbow, Kelly Posner, Eliot Moon.   

Abstract

OBJECTIVE: This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD.
METHOD: Participants were dose optimized over 5 weeks utilizing patch doses of 10, 16, 20, and 27 mg applied in the morning and worn for 9 hours. Following optimization, 80 participants were randomized to 1 week of MTS or placebo followed by 1 week of the opposite treatment. Laboratory classroom sessions conducted after each randomized week included blinded ratings of attention, behavior, and academic performance.
RESULTS: MTS was well tolerated and displayed significant improvement compared with placebo. Improvements were seen at the first postdose time point measured and continued through 12 hours.
CONCLUSIONS: Treatment with MTS resulted in statistically significant improvements on all efficacy measures. Time course and therapeutic effects of MTS suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481664     DOI: 10.1177/1087054705284089

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  32 in total

1.  Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD.

Authors:  Erin M Warshaw; Liza Squires; Yunfeng Li; Richard Civil; Amy S Paller
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

3.  Estimating the size of treatment effects: moving beyond p values.

Authors:  James J McGough; Stephen V Faraone
Journal:  Psychiatry (Edgmont)       Date:  2009-10

4.  ADHD in children: a path to free medicines.

Authors:  J Hayden; M Flood; F McNicholas
Journal:  Ir J Med Sci       Date:  2015-02-12       Impact factor: 1.568

Review 5.  A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Franziska Minder; Agnieszka Zuberer; Daniel Brandeis; Renate Drechsler
Journal:  Child Psychiatry Hum Dev       Date:  2018-08

Review 6.  ADHD in children and adolescents.

Authors:  Daphne Keen; Irene Hadijikoumi
Journal:  BMJ Clin Evid       Date:  2008-10-02

Review 7.  Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?

Authors:  Raman Baweja; Richard E Mattison; James G Waxmonsky
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

Review 8.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Authors:  Oscar G Bukstein; L Eugene Arnold; Jeanne M Landgraf; Paul Hodgkins
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-12-10       Impact factor: 3.033

10.  A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Scott H Kollins; Ann C Childress; Liza Squires
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-06-09       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.